--- title: "Retension Pharmaceuticals, Clinical-Stage Biopharma for Hypertension, Files for Nasdaq Capital Market IPO" type: "News" locale: "en" url: "https://longbridge.com/en/news/299490890.md" description: "Retension Pharmaceuticals, a clinical-stage biotech based in Falls Church, VA, has filed an S-1 to IPO on the Nasdaq Capital Market under ticker 'RTSN'. The company is developing RTN-001, a next-generation PDE-5 inhibitor for hypertension. Proceeds will fund Phase 2b completion and Phase 3 preparation. Underwriters include Leerink Partners, Guggenheim Securities, Oppenheimer & Co., and Titan Partners." datetime: "2026-09-18T21:18:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299490890.md) - [en](https://longbridge.com/en/news/299490890.md) - [zh-HK](https://longbridge.com/zh-HK/news/299490890.md) generator: "portal-rs" --- # Retension Pharmaceuticals, Clinical-Stage Biopharma for Hypertension, Files for Nasdaq Capital Market IPO Retension Pharmaceuticals filed an S-1 to go public on the Nasdaq Capital Market under the ticker “RTSN.” The Falls Church, VA-based clinical-stage biotech is developing RTN-001, a next-generation PDE-5 inhibitor designed to improve blood pressure control by enhancing nitric oxide-cGMP signaling. Proceeds are earmarked to complete a Phase 2b study and prepare for Phase 3, with Leerink Partners, Guggenheim Securities, Oppenheimer & Co., and Titan Partners as underwriters. **Business Description** Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing RTN-001, a once-daily, oral, next-generation PDE-5 inhibitor aimed at improving blood pressure control in uncontrolled and resistant hypertension. Unlike first-generation PDE-5 inhibitors, RTN-001 was designed via a proprietary surface chemistry-driven platform to enhance bioavailability and distribution to cardiovascular smooth muscle tissues in the central vasculature, with the goal of potentiating endogenous nitric oxide-cGMP signaling for more consistent and sustained blood pressure reduction. The company is running a randomized, double-blind, placebo-controlled Phase 2b study in uncontrolled hypertension to identify optimal dosing of a modified-release formulation intended to support 24-hour control and improved tolerability. Earlier Phase 2 pilot trials showed clinically meaningful, placebo-adjusted reductions in both peripheral and central blood pressure and a tolerability profile consistent with the PDE-5 inhibitor class. Retension plans to use Phase 2b results to inform a Phase 3 trial and is also exploring additional cardiovascular or renal indications where nitric oxide-cGMP pathway modulation may be beneficial. **Market Overview** - **Total addressable market**: Hypertension affects ~1.4 billion adults globally and ~120 million adults in the U.S. - **Market growth**: Heightened clinical focus from tighter AHA targets (130/80 mmHg) and FDA guidance recognizing BP reduction as a surrogate endpoint. - **Market position**: Clinical-stage developer of a next-generation PDE-5 inhibitor (RTN-001) engineered for central vascular smooth muscle distribution. - **Key competitors**: Established antihypertensive classes (ACE inhibitors, ARBs, calcium channel blockers, diuretics, beta blockers) and other emerging cardiometabolic approaches. - **Industry trends**: Emphasis on 24-hour blood pressure control, central blood pressure relevance, streamlined FDA pathways, and combination therapy strategies. **Operational Metrics** - **Customers**: Pre-revenue; no commercial customers - **Locations**: Headquarters in Falls Church, Virginia - **Geographic presence**: Ongoing U.S. Phase 2b trial; prior Phase 2 pilot trials conducted in the UK and Germany - **Partnerships**: Exclusive sublicense for RTN-001 via Redux/Kadmon; relies on third-party CROs and CMOs - **Orders/GMV**: Not applicable (pre-commercial) - **Other key metrics**: Phase 2b initiated in October 2025 across ~31 U.S. sites; ~40% enrolled as of September 11, 2026; 243 participants exposed to RTN-001 across nine completed trials; 12 employees as of September 16, 2026 **Financials Highlights** - **Revenue (current)**: None - **Operating income**: $(7.8) million loss (six months ended June 30, 2026) - **Net income**: $(7.5) million loss (six months ended June 30, 2026); $(6.3) million loss (FY2025) **Management** - **Eric Keller**, Chief Executive Officer - Biopharma executive and company co-founder; led prior deals at Surface Logix/Nano Terra and holds a J.D. from Boston College. - **Paul Sweetnam, Ph.D.**, Chief Scientific Officer - Former CSO at Surface Logix; led the early development of RTN-001; prior roles at Bayer, Pfizer, and Nova. - **Alison D. Schecter, M.D.**, Chief Medical Officer - Cardiovascular drug development leader; prior roles at Mineralys, Selecta, Sanofi-Genzyme; physician-scientist with extensive clinical leadership. - **Alex Schwartz**, Chief Financial Officer - Capital markets and biotech FP&A/IR experience at Ventyx, Allakos, NGM Biopharmaceuticals, and Esperion; former biotech equity analyst. - **Sabine Bisson, Ph.D.**, Chief Operating Officer - Nearly 20 years in biopharma development; led programs at Regeneron, Cellectis, and Volastra; experience across oncology and cardiometabolic assets. - **Michael Joseph Berendt, Ph.D.**, Executive Chairman - Industry veteran and former senior R&D leader at Bayer and Pfizer; multiple biotech CEO/board roles. **IPO Structure** - **Issuer**: Retension Pharmaceuticals, Inc. - **Filing date**: September 18, 2026 - **Proposed ticker**: RTSN - **Exchange**: Nasdaq Capital Market - **Lead underwriters**: Leerink Partners, Guggenheim Securities, Oppenheimer & Co., Titan Partners - **Use of proceeds**: Complete the Phase 2b clinical trial and prepare, support, and advance the planned Phase 3 trial of RTN-001; remainder for general corporate purposes. Original SEC Filing: Retension Pharmaceuticals, Inc. - S-1 - Sep. 18, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [OPY.US](https://longbridge.com/en/quote/OPY.US.md) - [BAYN.DE](https://longbridge.com/en/quote/BAYN.DE.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [MLYS.US](https://longbridge.com/en/quote/MLYS.US.md) - [SNY.US](https://longbridge.com/en/quote/SNY.US.md) - [VTYX.US](https://longbridge.com/en/quote/VTYX.US.md) - [ALLK.US](https://longbridge.com/en/quote/ALLK.US.md) - [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md) - [REGN.US](https://longbridge.com/en/quote/REGN.US.md) - [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md) - [BAYZF.US](https://longbridge.com/en/quote/BAYZF.US.md) - [BAYRY.US](https://longbridge.com/en/quote/BAYRY.US.md) - [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md) ## Related News & Research - [Oppenheimer 2Q FY26 net income rises 26.2% to $27.35 million; revenue increases 21.9% to $454.88 million](https://longbridge.com/en/news/294509804.md) - [‘Open Your Eyes,’ Says Top Investor About Oracle Stock](https://longbridge.com/en/news/301160283.md) - [Bank of New Hampshire Reduces Stock Holdings in Micron Technology, Inc. $MU](https://longbridge.com/en/news/301083752.md) - [Marvell Now Sees as Much as $90 Billion in Annual Sales by Fiscal 2031. Here's Why It's a Chip Stock to Buy.](https://longbridge.com/en/news/301114413.md) - [Palantir vs. Oracle – Why Daniel Ives Says Buy One, Hold the Other](https://longbridge.com/en/news/301155464.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**